# Signals Article: Putative Target P06733 for Endometriosis
Background
Endometriosis is a chronic gynecological condition characterized by the presence of endometrial-like tissue outside the uterus, leading to pain and infertility. Despite its prevalence, the pathogenesis of endometriosis remains poorly understood, and current treatments are limited. Identifying novel molecular targets is crucial for developing more effective therapies. In this context, the protein encoded by UniProt entry P06733 has emerged as a putative target for further investigation in endometriosis.
Data-mining rationale
Our investigative approach involved cross-referencing reviewed human entries in UniProt associated with "endometriosis" against 85 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate protein P06733 was identified in expression-profiling studies related to endometriosis, suggesting its potential involvement in the disease. Notably, this target has not been explored in any registered Phase 1 or higher clinical programs, highlighting an opportunity for novel research.
Why prior analyses may have missed this
Many of the GEO datasets analyzed predate the widespread adoption of modern empirical-Bayes statistical methods, such as the linear models for microarray data (limma) approach. These older datasets often lack proper multiple-testing correction, which can lead to false negatives in identifying differentially expressed genes. By re-analyzing these datasets with updated statistical techniques, including the Benjamini-Hochberg false discovery rate (FDR) correction, we can more accurately identify potential targets like P06733 that may have been overlooked in previous analyses.
Reasoning for further validation
To substantiate the role of P06733 in endometriosis, several experimental steps are recommended:
1. **Re-analysis of GEO datasets**: Utilize limma with Benjamini-Hochberg FDR < 0.05 to identify top differentially expressed genes associated with endometriosis.
2. **Validation by qPCR**: Confirm the expression levels of P06733 in an independent cohort of endometriosis patients and controls to ensure reproducibility and accuracy.
3. **Tissue specificity assessment**: Use resources like GTEx and the Human Protein Atlas to determine the tissue-specific expression patterns of P06733, which can provide insights into its potential role in endometriosis.
4. **Pathway context exploration**: Conduct pathway analysis using tools such as STRING and OmniPath to understand the biological networks and interactions involving P06733.
5. **Druggability assessment**: If validated, evaluate the druggability of P06733 using databases like DGIdb and ChEMBL to explore potential therapeutic interventions.
These steps will help clarify the biological significance of P06733 in endometriosis and assess its viability as a therapeutic target.